Commentary: Use of biosimilars for retinal diseases in India: Challenges and concerns

Indian J Ophthalmol. 2021 Feb;69(2):357-358. doi: 10.4103/ijo.IJO_39_21.
No abstract available

Publication types

  • Comment

MeSH terms

  • Bevacizumab
  • Biosimilar Pharmaceuticals*
  • Humans
  • India / epidemiology
  • Retinal Diseases* / drug therapy
  • Retinal Diseases* / epidemiology

Substances

  • Biosimilar Pharmaceuticals
  • Bevacizumab